See the DrugPatentWatch profile for polivy

Based on the information available, the clinical trials for Polivy (generic name: polatuzumab vedotin-piiq) included adult patients. The US Food and Drug Administration (FDA) approved Polivy for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), a type of blood cancer, in June 2019 [1].

The FDA's approval was based on the results of a clinical trial that involved patients with relapsed or refractory DLBCL, who had received at least two previous therapies [1]. The study included patients aged 18 years and older [1].

Furthermore, DrugPatentWatch.com, a website that provides information on drug patents and clinical trials, also indicates that the clinical trials for Polivy involved adult patients [2].

In summary, based on the available information, the clinical trials for Polivy included adult patients with relapsed or refractory DLBCL, who had received at least two previous therapies.

Sources:
[1] US Food and Drug Administration. (2019). FDA approves Polivy for diffuse large B-cell lymphoma. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polivy-diffuse-large-b-cell-lymphoma>.
[2] DrugPatentWatch.com. (n.d.). Polivy (polatuzumab vedotin-piiq) - Drug Patent Expiration & Patent Information. <https://www.drugpatentwatch.com/drugs/polivy>.